Zacks Research Lifts Earnings Estimates for Atossa Genetics

Atossa Genetics Inc. (NASDAQ:ATOS) – Zacks Research lifted their Q3 2026 EPS estimates for Atossa Genetics in a research report issued on Friday, August 14th. Zacks Research analyst D. Bautz now anticipates that the company will earn ($0.74) per share for the quarter, up from their previous forecast of ($1.02). The consensus estimate for Atossa Genetics’ current full-year earnings is ($4.30) per share. Zacks Research also issued estimates for Atossa Genetics’ Q4 2026 earnings at ($0.73) EPS, FY2026 earnings at ($3.49) EPS, FY2027 earnings at ($2.73) EPS and FY2028 earnings at ($2.38) EPS.

Atossa Genetics (NASDAQ:ATOS) last released its earnings results on Friday, August 7th. The company reported ($0.95) EPS for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.07.

Other equities research analysts have also issued reports about the stock. Rodman & Renshaw began coverage on shares of Atossa Genetics in a report on Tuesday, July 7th. They set a “buy” rating and a $12.00 price objective on the stock. Wall Street Zen upgraded Atossa Genetics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings lowered Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Three investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $20.33.

Atossa Genetics Trading Up 1.9%

Shares of Atossa Genetics stock opened at $2.64 on Thursday. The firm’s 50 day simple moving average is $2.28 and its two-hundred day simple moving average is $4.08. The firm has a market capitalization of $26.34 million, a price-to-earnings ratio of -0.85 and a beta of 1.29. Atossa Genetics has a 12-month low of $1.70 and a 12-month high of $19.35.

Hedge Funds Weigh In On Atossa Genetics

A number of institutional investors have recently bought and sold shares of ATOS. &PARTNERS purchased a new stake in shares of Atossa Genetics in the 4th quarter valued at $25,000. Hudson Bay Capital Management LP purchased a new position in shares of Atossa Genetics during the second quarter worth $26,000. JPMorgan Chase & Co. raised its holdings in shares of Atossa Genetics by 1,294.2% during the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after purchasing an additional 35,474 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Atossa Genetics by 55.7% during the second quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock worth $83,000 after purchasing an additional 35,629 shares during the last quarter. Finally, XTX Topco Ltd lifted its position in Atossa Genetics by 581.2% during the fourth quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock valued at $100,000 after purchasing an additional 144,412 shares during the period. 12.74% of the stock is owned by hedge funds and other institutional investors.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.